I met Balvinder Dang, co-founder and chief executive of Datavid, at the Progress Data Summit last year. I am genuinely pleased to see this milestone for him and his team.

On March 19, C5i announced it is acquiring Datavid, a London based data and AI company. The deal is expected to close this month. Datavid's own announcement describes it as joining forces. That is softer than accurate. C5i is buying Datavid outright, and the distinction matters because it changes how clients, staff, and competitors should read the news.

C5i looked at more than 50 companies before choosing Datavid. That is not a casual process. They knew what they needed.

The Problem in Plain Terms

Think about a large pharmaceutical company. C5i has spent years helping the commercial side of that business: which doctors to call on, how to allocate marketing spend, how to measure sales force effectiveness. Datavid has spent years helping the research side: connecting clinical trial records, scientific papers, and regulatory documents so that drug discovery teams can find answers faster and get new therapies through review more quickly.

Those two sides of the same company have rarely talked to each other, and their data has almost never been connected. Before this deal, a pharmaceutical chief information officer who wanted help with both had to manage two separate vendors. After it, C5i can serve both sides with one team and one connected data foundation. That is the actual deal logic, and it is more compelling than most acquisition announcements communicate.

Why Timing Matters

C5i has been building AI systems that take actions automatically on behalf of clients, in areas like supply chain and customer management. Those systems are only as reliable as the data they reason over. Most enterprise data is messy, incomplete, and disconnected. Datavid's core skill is cleaning that up at a structural level, connecting data across sources so that AI systems have something solid to work with rather than something they are forced to guess around.

Building that capability from scratch would have taken C5i years. Acquiring a team that has already done it in regulated industries, where the data stakes are highest, shortens that runway considerably.

What the Announcement Leaves Out

Connecting and maintaining data at this level is not cheap. It requires ongoing investment as data changes, organizations restructure, and regulations shift. The announcement says nothing about how that ongoing cost is handled or how it is priced for clients. That is the question informed buyers will ask first.

C5i is also reportedly targeting significant revenue growth and planning a public offering in 2026. An acquisition that deepens enterprise AI credibility right before an initial public offering serves investor audiences as much as client ones. Both are legitimate motivations. They are worth naming separately.

What to Watch

The deal makes strategic sense on paper. The test is whether C5i can deliver the combined capability without requiring every client to fund a large, custom data project just to get started. If the combined offering is accessible and repeatable, this acquisition moves C5i into a stronger position in life sciences and beyond. If every deployment still requires heavy professional services to set up the data foundation, the announcement is ahead of the product reality. Watch the next wave of client announcements to see which story holds.